KPI-121

DRUG2 trials

Sponsors

Kala Pharmaceuticals, Inc.

Conditions

BlepharitisDry Eye SyndromesKeratoconjunctivitis Sicca

Phase 2

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

CompletedNCT02188160

Kala Pharmaceuticals, Inc.Dry Eye Syndromes, Keratoconjunctivitis Sicca

Start: 2014-06-30End: 2015-03-31Updated: 2021-01-06

Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease

CompletedNCT02218489

Kala Pharmaceuticals, Inc.Blepharitis

Start: 2014-07-31End: 2016-06-30Updated: 2021-01-11